Quotient (QTNT) Getting Somewhat Favorable Media Coverage, Report Shows
News coverage about Quotient (NASDAQ:QTNT) has been trending somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of press coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Quotient earned a news impact score of 0.15 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.804703137293 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Several equities research analysts have commented on the stock. Zacks Investment Research cut shares of Quotient from a “hold” rating to a “sell” rating in a research report on Thursday, November 2nd. Jefferies Group cut their price target on shares of Quotient from $15.00 to $13.00 and set a “buy” rating on the stock in a research report on Wednesday, November 1st. Finally, BTIG Research reissued a “buy” rating and set a $12.00 price target on shares of Quotient in a research report on Wednesday, November 1st.
Shares of Quotient (QTNT) traded up $0.04 during trading hours on Friday, reaching $4.12. 485,538 shares of the company’s stock traded hands, compared to its average volume of 277,686. The company has a quick ratio of 0.86, a current ratio of 1.36 and a debt-to-equity ratio of -5.17. Quotient has a 52-week low of $3.22 and a 52-week high of $7.74. The company has a market cap of $185.88, a PE ratio of -1.43 and a beta of 1.40.
Quotient Company Profile
Quotient Limited is a diagnostics company. The Company focuses on blood grouping and donor disease screening, which is referred to as transfusion diagnostics. It is engaged in developing, manufacturing and commercializing conventional reagent products used for blood grouping within the global transfusion diagnostics market.
Receive News & Ratings for Quotient Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quotient and related companies with MarketBeat.com's FREE daily email newsletter.